Exalenz Bioscience sold at NIS 165m valuation

The price at which the company is being sold is 97% lower than the price at which trading in the share began in 2007.

Teeth whitening co Mavrik Dental Systems raises $30m

Global life science investment group Ally Bridge Group has invested $70 million in two Israeli companies.

drug development Israeli co NeoTX Therapeutics raises $45m

The Rehovot-based company is leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies.

Noam Zilbershtain / Photo: PR GE expands advanced imaging activities in Israel

The Israel Innovation Authority has granted GE NIS 50 million to expand its Rehovot center.

Copaxone Proneuron to sue Teva for billions in Copaxone damages

A court ordered Teva to restore the Copaxone rights for treatment of diseases other than multiple sclerosis to Proneuron, but the patent has expired, rendering the rights useless.

Warren Buffett Photo: ASAP Creative Value of Warren Buffett's position in Teva jumps

However, Berkshire Hathaway still has a loss on paper on its investment in Teva of about $230 million.

Eli Kalif  / Photo: PR Teva CFO: Wind blowing towards growth

Eli Kalif tells "Globes" that growth will be enhanced by streamlining factories rather than more closures and selloffs.

Teva Photo: Sivan Faraj Teva beats analysts on Q4 revenue and profit

The Israeli pharmaceutical company sees higher revenue and profit in 2020.

Ronni Gamzu Hospital chief enraged by 'collapsing health system' claims

Ichilov Hospital CEO Ronni Gamzu is furious about Benny Gantz's populist comments and says that education and transport have bigger problems than the health services.

Tomer Hertz Is it worth getting vaccinated against flu?

Ben Gurion University researcher Dr. Tomer Hertz says flu jabs, like vaccinations against childhood diseases, are a social act that helps prevent infecting others.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018